Abstract: Embodiments herein provide a power control system (100) for controlling reactive power and/or active power in a power network. The power control system (100) is operatively coupled to the power network at a point of common coupling, PCC. The power control system (100) comprises a transformer (10) with at least three windings, in which a primary winding of the transformer (10) being connected to an input from the power network. The power control system (100) further comprises a voltage-source converter, VSC (20), being connected to a secondary winding of the transformer (10), wherein the VSC (20) is configured to work as a source or a sink of reactive power in the power network. The power control system (100) further comprises a Current Source Converter, CSC, (30) being connected to a tertiary winding of the transformer (10) and the CSC (30) is configured to handle power imbalance in the power network. Corresponding power compensator module is also disclosed.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Abstract: Detailed herein is a technology which, among other things, allows a search engine to utilize a user-defined relevance function. In one approach to the technology, a method of applying a user-defined relevance function is described. In this approach, a complex search query is decomposed into a simple operator. The simple operator is associated with the user-defined relevance function. A document which matches the search query is retrieved, and a rank is calculated for the document, using the user-defined relevance function.

Abstract: Consistency between the components used to generate and query a full-text index is determined and if a mismatch is detected, an error may be surfaced. A structure including information associated with each component used to build an index is programmatically compared with currently available components. The structure may be interrogated to enumerate the resources bound to a particular index. The enumeration of bound resources facilitates determination of what indexes (if any) must be regenerated for consistency as a result of a component upgrade or a move to another system.

Abstract: Detailed herein is a technology which, among other things, allows a search engine to utilize a user-defined relevance function. In one approach to the technology, a method of applying a user-defined relevance function is described. In this approach, a complex search query is decomposed into a simple operator. The simple operator is associated with the user-defined relevance function. A document which matches the search query is retrieved, and a rank is calculated for the document, using the user-defined relevance function.